Insulin Aspart Prot/Insuln Asp
Brand name: Novolog Mix 70-30 Flexpen
Rank #178 of 500 drugs by total cost
$88.8M
Total Cost
79,814
Total Claims
$88.8M
Total Cost
3,618
Prescribers
$1,112
Cost per Claim
5,305
Beneficiaries
117,937
30-Day Fills
$25K
Avg Cost/Provider
22
Avg Claims/Provider
About Insulin Aspart Prot/Insuln Asp
Insulin Aspart Prot/Insuln Asp (sold as Novolog Mix 70-30 Flexpen) was prescribed 79,814 times by 3,618 Medicare Part D providers in 2023, costing the program $88.8M. At $1,112 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
| 179 | Teduglutide (Gattex) | $88.4M | 1,758 |
| 180 | Galcanezumab-Gnlm (Emgality Pen) | $87.0M | 101,221 |
| 181 | Imatinib Mesylate (Imatinib Mesylate) | $85.0M | 40,908 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology